Multiple episodes of thrombosis with biventricular support devices with inadequate anticoagulation and evidence of accelerated intravascular coagulation  by Despotis, George J. et al.
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 113, Number 2 
Brief communications 4 1 9 
benefit for patients with an increased risk for degenera- 
tion of the valves. At present it is impossible to assess 
prospectively which patients are at risk for immune- 
mediated valve degeneration. However, children listed for 
retransplantation for reasons other than technical failure 
and children with preformed HLA antibodies are likely 
candidates. We recommend that for these patients at 
"high risk" a crossmatch-negative, HLA-matched heart 
valve allograft be selected. 
The cooperation of the Stichting Rode Kruis Bloed- 
bank Noord Nederland, their blood donors, and Bio 
Implant Services for providing the HLA types of the 
donors is gratefully acknowledged. 
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MULTIPLE EPISODES OF THROMBOSIS WITH BIVENTRICULAR SUPPORT DEVICES WITH 
INADEQUATE ANTICOAGULATION AND EVIDENCE OF ACCELERATED INTRAVASCULAR 
COAGULATION 
George J. Despotis, MD, Vladimir Levine, MD, PhD, Heinrich Joist, MD, PhD, Samuel A. Santoro, MD, PhD, and 
Eric Mendeloff, MD, St. Louis, Mo. 
Ventricular assist devices (VADs) may induce com- 
plex hemostatic abnormalities mediated by excessive 
activation of platelets, coagulation, and fibrinolysis with 
resulting consumption of platelets and labile coagula- 
tion factors and sometimes associated with thrombo- 
sis. 1-3 We describe the case of a teenaged boy with 
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dilated cardiomyopathy whose course was initially com- 
plicated by excessive bleeding. He subsequently had 
multiple episodes of thrombosis of biventricular assist 
devices (BVADs) that were associated with accelerated 
intravascular coagulation temporally related to subop- 
timal warfarin anticoagulation. 
A 15-year-old boy with Becker's muscular dystrophy 
was admitted for treatment of progressive congestive 
heart failure. Transthoracic echocardiography revealed 
dilated cardiomyopathy with severely reduced ejection 
fraction and a right ventricular mural thrombus. Over a 
3-week period after admission, he began having increas- 
ingly severe symptoms of congestive heart failure with 
respiratory distress and profound hypotension. The symp- 
toms were unresponsive to aggressive medical manage- 
ment with inotropic support, diuresis, afterload reduction, 
and intraaortic balloon counterpulsation. After the devel- 
opment of cardiogenic shock, ABIOMED BVADs 
(ABIOMED Cardiovascular, Inc., Danvers, Mass.) were 
implanted as a bridge to transplantation (day 1). The 
patient was given a continuous infusion of heparin at a 
rate of 1500 to 2200 U/hr to maintain the celite activated 
clotting time between 180 and 200 seconds. While he was 
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Fig. 1. Alterations in hemostatic measurements and heparin concentrations during hospitalization days 8 
to 80 in relation to abnormal bleeding and VAD thrombosis in a patient with BVADs for heart failure 
caused by cardiomyopathy. Top left ordinate, Prothrombin international normalized ratio (PT-INR) and 
anti-factor Xa heparin concentration (anti-Xa) (U/ml). Top right ordinate, Antithrombin II I (AT3) (U/ml) 
and platelet count (PLT/IO) (thousands/txl/10). Bottom left ordinate, j3-thromboglobulin (BTG) (IU/ml) and 
fibrin degradation products in D-dimer (ng/ml). Bottom right ordinate, Fibrinopeptide A (FPA) (ng/ml); 
ASA, aspirin; vit K, vitamin K (1 mg). 
receiving antifibrinolytic therapy (epsilon-aminocaproic 
acid), heparin anticoagulation, and transfusion of fresh 
frozen plasma and platelet concentrates, his initial course 
(days 1 to 8) was complicated by recurrent episodes of 
severe bleeding that necessitated exploration on five oc- 
casions. No surgical source of bleeding could be identified, 
yet clots were visible in the BVAD system. Informed 
consent was obtained, and blood specimens were collected 
daily for a more detailed evaluation of the patient's 
coagulation status. Sensitive markers of activation of 
platelets, coagulation, and fibrinolysis were used for these 
evaluations (Fig. 1). Shortly after heparin was supple- 
mented with warfarin on the basis of a presumptive 
diagnosis of consumptive coagulopathy caused by inade- 
quate anticoagulation, the excessive bleeding stopped. 
Despite warfarin anticoagulation to maintain the pro- 
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thrombin time international normalized ratio (PT-INR) at 
2 to 3 and therapeutic blood heparin concentrations 
(anti-factor Xa, 0.35 -- 0.02 U/ml; anti-factor IIa, 0.42 _+ 
0.04 U/ml), the patient began having recurrent thrombosis 
of the BVAD system, necessitating device replacement 
(Fig. 1, top). The initial episode of BVAD thrombosis was 
temporally related to reversal of warfarin with intravenous 
vitamin K, which was administered because of a progres- 
sive and persistent elevation in the PT-INR. Subse- 
quently, heparin-induced thrombocytopenia w s ruled 
out by means of a serotonin-release assay, along with 
deficiency of either protein C or S, and aspirin was 
added to the anticoagulation regimen. The four subse- 
quent episodes of BVAD thrombosis were also tempo- 
rally related to the intensity of warfarin anticoagula- 
tion, specifically with INRs below 2.5 (see Fig. 1). In 
addition, INRs were related directly to platelet counts 
(r = 0.53,p < 0.0001) and indirectly to/3-thromboglob- 
ulin (BTG)(r = -0.64, p < 0.0001) and fibrinopeptide 
A (FPA)(r = -0.66,p < 0.0001)(Fig. 2). Platelet counts 
were also indirectly related to FPA values (r = -0.60, 
p < 0.0001). The considerable fluctuations in INRs may 
have been related to the patient's fluctuating nutritional 
status (vitamin K intake), which was affected by peri- 
odic requirements for mechanical ventilatory support. 
The patient underwent successful heart transplantation 
on day 80 and was discharged without evidence of 
transient ischemic attacks or strokes after an uneventful 
postoperative course. 
Activation of platelets and the intrinsic and extrinsic 
coagulation pathways by VADs can result in bleeding 3' 4 
or thrombotic omplications (or both). ~-3 Heparin an- 
ticoagulation is frequently used to prevent excessive 
hemostatic system activation and thrombosis with 
VADs because its anticoagulant effect can be rapidly 
reversed, which may be necessary when frequently 
encountered 4 bleeding complications occur. However, 
the optimal therapeutic doses for heparin anticoagula- 
tion with VADs have not been well defined. In addition, 
heparin anticoagulation does not adequately suppress 
excessive thrombin generation during extracorporeal 
circulation, nor does it necessarily prevent hrombosis, 
as previously described in a patient with end-stage 
cardiomyopathy who required ABIOMED BVADs. 2 
Our findings indicate that the multiple episodes of 
thrombosis in this patient may have been related to an 
underlying state of excessive hemostatic system activa- 
tion, caused at least in part by inadequate anticoagula- 
tion, as demonstrated by (1) a dose-time association 
between reduced INR and thrombotic events and (2) a 
time association between thrombotic events and eleva- 
tions of FPA, D-dimers, and BTG with a concurrent 
decreases in platelet count and antithrombin III. Fur- 
thermore, sensitive markers of platelet and coagulation 
activation were markedly increased when INRs were 
below 2.5 (Fig. 2). Platelet counts, which have previ- 
ously been shown to be associated with an increased 
risk of thrombus formation, ~correlated with INRs and 
were indirectly related to FPA in the present study. 
This observation suggests that thrombin may have 
partially mediated activation and consumption of plate- 
lets. Thus our findings support previous suggestions 3 
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Fig. 2. Relations between fibrinopeptide A (FPA) (upper 
panel) and 13-thromboglobulin (BTG) (lower panel) and 
PT-INR. Vertical line demarcates an INR of 2.5. 
that a greater degree of warfarin anticoagulation (INR 
2.5 to 3.5) may be required to prevent hrombosis with 
VADs. It is of interest that the patient's excessive 
bleeding subsided within the first 2 days after initiation 
of warfarin therapy. This effect may have been related 
to further suppression of the consumptive state. The 
concept of enhanced anticoagulation resulting in better 
preservation of hemostasis and reduced bleeding is 
supported by recent findings, which demonstrate that 
maintenance of higher, patient-specific heparin concen- 
trations during extracorporeal circulation can reduce 
consumption of coagulation factors by better suppres- 
sion of thrombin activity. 5 Further prospective studies 
are needed for several reasons: (1) to determine more 
accurately the incidence of abnormal bleeding and 
thrombosis with VADs, (2) to characterize the thera- 
peutic range for warfarin anticoagulation with VADs 
and determine if a specific INR (e.g., 2.5) is optimal for 
reducing thrombotic complications and suppressing 
platelet and coagulation activation using sensitive bio- 
chemical markers in a series of patients upported with 
VADs, and (3) to evaluate alternate forms of single- 
agent or combined antithrombotic therapy, such as 
reversible, specific inhibition of thrombin and platelets, 
as well as antithrombin III supplementation a d/or use 
of heparin-bound extracorporeal circuits. 
422 Brief communications 
The Journal of Thoracic and 
Cardiovascular Surgery 
February 1997 
REFERENCES 
1. Sato N, Mohri H, Fujimasa I, et al. Multivariate analysis of risk 
factors for thrombus formation in University of Tokyo ventricular 
assist device. J Thorac Cardiovasc Surg 1993;106:520-7. 
2. Despotis GJ, Levine V, Alsoufiev A, Joist J, Goodnough LT, 
Pasque M. Recurrent hrombosis of biventricular support 
devices associated with accelerated intravascular coagulation 
and increased heparin requirements. J Thorac Cardiovasc 
Surg 1996;112:538-40. 
3. Copeland JG III. Thromboembolism and bleeding: clinical 
strategies. Ann Thorac Surg 1996;61:376-7. 
4. Bartlett RH. Extracorporeal life support for cardiopulmonary 
failure. Curr Probl Surg 1990;27:621-705. 
5. Despotis GJ, Joist JH, Hogue CW, et al. More effective suppres- 
sion of hemostatic system activation in patients undergoing 
cardiac surgery by heparin dosing based on heparin blood 
concentrations rather than ACT. Thromb Haemostas 1996;76: 
902-8. 
